VIRGINIA RETIREMENT SYSTEMS ET Al Buys New Position in Zoetis Inc. $ZTS

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Zoetis Inc. (NYSE:ZTS) in the 2nd quarter, Holdings Channel reports. The fund bought 71,200 shares of the company’s stock, valued at approximately $5,116,000.

Other hedge funds also recently modified their holdings of the company. Brighton Jones LLC raised its stake in Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares during the period. Empowered Funds LLC grew its position in Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after purchasing an additional 657 shares during the period. Intech Investment Management LLC grew its position in Zoetis by 17.2% in the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after purchasing an additional 1,224 shares during the period. Sivia Capital Partners LLC increased its stake in Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after purchasing an additional 1,422 shares in the last quarter. Finally, Glenview Trust co raised its holdings in Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after buying an additional 506 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ZTS. BNP Paribas Exane reduced their price objective on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a report on Tuesday, August 11th. HSBC lowered their target price on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, July 6th. Zacks Research downgraded Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. TD Cowen decreased their price objective on Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a report on Tuesday, August 25th. Finally, Piper Sandler lowered their price objective on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $101.08.

Zoetis Trading Down 3.0%

Shares of ZTS stock opened at $73.56 on Wednesday. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The company has a market capitalization of $30.40 billion, a price-to-earnings ratio of 12.12, a PEG ratio of 1.77 and a beta of 0.73. Zoetis Inc. has a 52-week low of $71.00 and a 52-week high of $152.12. The company has a 50-day simple moving average of $75.61 and a two-hundred day simple moving average of $92.87.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Research analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.